![Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal](https://media.bizj.us/view/img/2741971/jon-p-stonehouse.jpg)
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal
![Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestorstorage.b-cdn.net/forecast-graphs/63/stock-bcrx-stock-forecast-components.png?v=1698696095)
Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
BioCryst Pharmaceuticals Shares Rise After BofA Securities Upgrade -July 13, 2023 at 10:37 am EDT | MarketScreener
![Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestorstorage.b-cdn.net/forecast-graphs/63/stock-bcrx-stock-forecast.png?v=1698696095)